Research

Macro partitioning

Combined GIPR/GLP1R agonism lowers plasma triglyceride levels by increasing VLDL turnover (reduced hepatic VLDL-TG production and increased uptake by adipose tissue and liver).

Dual GIP/GLP-1 agonism improves lipid profiles by accelerating the clearance of triglyceride-rich lipoproteins (VLDL). This suggests that patients on these therapies may see significant improvements in triglyceride levels, which is a key risk factor for cardiovascular disease.

ModerateSupportsMEDIUM confidence
Combined GIPR/GLP1R agonism markedly lowered plasma triglyceride (TG) levels as explained by reduced hepatic very-low-density lipoprotein (VLDL)-TG production as well as increased TG-derived fatty acid uptake by brown and white adipose tissue which was coupled to enhanced hepatic uptake of core VLDL remnants.
Robin van Eenige et al. · Atherosclerosis · 2023

Why this rating

Robust mechanistic data in mice, but pre-clinical.

Source

Combined glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 receptor agonism attenuates atherosclerosis severity in APOE*3-Leiden.CETP mice

Robin van Eenige et al. · Atherosclerosis · 2023

DOI 10.1016/j.atherosclerosis.2023.03.016

mechanism_only · n=64Cited 18×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →